{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:54:38Z","timestamp":1761062078503,"version":"3.44.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012651","name":"College of Veterinary Medicine, University of Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012651","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["R01DE023783-01A"],"award-info":[{"award-number":["R01DE023783-01A"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bonr.2025.101837","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T20:39:43Z","timestamp":1742243983000},"page":"101837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Mild antiresorptive activity of an anti-vascular endothelial growth factor A antibody and sunitinib in a rat model of bone resorption"],"prefix":"10.1016","volume":"25","author":[{"given":"J.I.","family":"Aguirre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.M.","family":"Croft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.J.","family":"Cruz-Camacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.B.","family":"Kimmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bonr.2025.101837_bb0005","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bonr.2025.101837_bb0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bonr.2025.101837_bb0015","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.coms.2015.06.001","article-title":"Pathophysiology of osteonecrosis of the jaws","volume":"27","author":"Aghaloo","year":"2015","journal-title":"Oral Maxillofac. Surg. Clin. North Am."},{"issue":"1","key":"10.1016\/j.bonr.2025.101837_bb0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0002-9440(10)63963-6","article-title":"Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity","volume":"158","author":"Aguirre","year":"2001","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.bonr.2025.101837_bb0025","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1359\/jbmr.070313","article-title":"Effects of basic fibroblast growth factor and a prostaglandin E2 receptor subtype 4 agonist on osteoblastogenesis and adipogenesis in aged ovariectomized rats","volume":"22","author":"Aguirre","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bonr.2025.101837_bb0030","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/jbmr.1669","article-title":"Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis","volume":"27","author":"Aguirre","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2025.101837_bb0035","article-title":"Biologic and pathologic aspects of osteocytes in the setting of medication-related osteonecrosis of the jaw (MRONJ)","volume":"153","author":"Aguirre","year":"2021","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bonr.2025.101837_bb0040","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00774-017-0872-1","article-title":"Effect of anti-angiogenesis induced by chemotherapeutic monotherapy, chemotherapeutic\/bisphosphonate combination therapy and anti-VEGFA mAb therapy on tooth extraction socket healing in mice","volume":"36","author":"Akita","year":"2018","journal-title":"J. Bone Miner. Metab."},{"issue":"2","key":"10.1016\/j.bonr.2025.101837_bb0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","article-title":"Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents","volume":"27","author":"Aragon-Ching","year":"2009","journal-title":"Cancer Investig."},{"issue":"9","key":"10.1016\/j.bonr.2025.101837_bb0050","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4161\/cbt.8.9.8246","article-title":"Sunitinib and PF-562,271 (FAK\/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model","volume":"8","author":"Bagi","year":"2009","journal-title":"Cancer Biol. Ther."},{"issue":"15","key":"10.1016\/j.bonr.2025.101837_bb0055","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1158\/1078-0432.CCR-09-3100","article-title":"Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy","volume":"16","author":"Bagri","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bonr.2025.101837_bb0060","series-title":"Bone Histomorphometry: Techniques and Interpretation","first-page":"13","article-title":"Processing of undecalcified bone specimens for bone histomorphometry","author":"Baron","year":"1983"},{"issue":"5","key":"10.1016\/j.bonr.2025.101837_bb0065","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000365889","article-title":"The use of bisphosphonates in pediatrics","volume":"82","author":"Baroncelli","year":"2014","journal-title":"Horm. Res. Paediatr."},{"issue":"10","key":"10.1016\/j.bonr.2025.101837_bb0070","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"22","key":"10.1016\/j.bonr.2025.101837_bb0075","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw--do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bonr.2025.101837_bb0080","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture intervention, fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. FIT research group","volume":"85","author":"Black","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"22","key":"10.1016\/j.bonr.2025.101837_bb0085","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","article-title":"Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?","volume":"366","author":"Black","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bonr.2025.101837_bb0090","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1755-5922.2011.00278.x","article-title":"Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function","volume":"30","author":"Blasi","year":"2012","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.bonr.2025.101837_bb0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bone.2015.01.024","article-title":"Osteoblast function and bone histomorphometry in a murine model of Rett syndrome","volume":"76","author":"Blue","year":"2015","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.bonr.2025.101837_bb0100","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.neo.2017.05.007","article-title":"Evaluation of the response of intracranial xenografts to VEGF signaling inhibition using multiparametric MRI","volume":"19","author":"Boult","year":"2017","journal-title":"Neoplasia"},{"issue":"5","key":"10.1016\/j.bonr.2025.101837_bb0105","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.pmrj.2013.10.009","article-title":"Bisphosphonate treatment for children with disabling conditions","volume":"6","author":"Boyce","year":"2014","journal-title":"PM R"},{"issue":"6","key":"10.1016\/j.bonr.2025.101837_bb0110","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s001980050175","article-title":"Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis","volume":"9","author":"Bravenboer","year":"1999","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bonr.2025.101837_bb0115","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00005792-199707000-00005","article-title":"Long-term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis","volume":"76","author":"Brumsen","year":"1997","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.bonr.2025.101837_bb0120","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J. Clin. Invest."},{"issue":"15","key":"10.1016\/j.bonr.2025.101837_bb0125","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1177\/15353702211011052","article-title":"Zoledronic acid modulates osteoclast apoptosis through activation of the NF-kappaB signaling pathway in ovariectomized rats","volume":"246","author":"Cheng","year":"2021","journal-title":"Exp. Biol. Med. (Maywood)"},{"issue":"3","key":"10.1016\/j.bonr.2025.101837_bb0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.bonr.2025.101837_bb0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jbo.2018.09.008","article-title":"Benefits and risks of adjuvant treatment with zoledronic acid in stage II\/III breast cancer","volume":"13","author":"Coleman","year":"2018","journal-title":"J Bone Oncol"},{"issue":"11","key":"10.1016\/j.bonr.2025.101837_bb0140","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.bonr.2025.101837_bb0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bonr.2025.101837_bb0150","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.oraloncology.2011.07.030","article-title":"A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit","volume":"48","author":"Disel","year":"2012","journal-title":"Oral Oncol."},{"issue":"10","key":"10.1016\/j.bonr.2025.101837_bb0155","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1158\/0008-5472.CAN-16-0255","article-title":"Differential expression of VEGFA isoforms regulates metastasis and response to anti-VEGFA therapy in sarcoma","volume":"77","author":"English","year":"2017","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bonr.2025.101837_bb0160","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"issue":"24","key":"10.1016\/j.bonr.2025.101837_bb0165","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bonr.2025.101837_bb0170","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bonr.2025.101837_bb0175","series-title":"Bone Histomorphometry: Techniques and Interpretation","first-page":"109","article-title":"Bone histomorphometry: analysis of trabecular bone dynamics","year":"1983"},{"issue":"4","key":"10.1016\/j.bonr.2025.101837_bb0180","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clgc.2014.12.002","article-title":"Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an Italian multicenter study and review of the literature","volume":"13","author":"Fusco","year":"2015","journal-title":"Clin. Genitourin. Cancer"},{"issue":"9","key":"10.1016\/j.bonr.2025.101837_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068103","article-title":"Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice","volume":"8","author":"Gregory","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.bonr.2025.101837_bb0190","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","article-title":"Bevacizumab-associated osteonecrosis of the jaw","volume":"19","author":"Greuter","year":"2008","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bonr.2025.101837_bb0195","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.bonr.2025.101837_bb0200","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00280-016-3079-6","article-title":"Population pharmacokinetics of bevacizumab in cancer patients with external validation","volume":"78","author":"Han","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"7","key":"10.1016\/j.bonr.2025.101837_bb0205","first-page":"2394","article-title":"Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases","volume":"9","author":"Ibrahim","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bonr.2025.101837_bb0210","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00198-006-0240-9","article-title":"A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats","volume":"18","author":"Iwaniec","year":"2007","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bonr.2025.101837_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.115850","article-title":"Bisphosphonates impair the onset of bone formation at remodeling sites","volume":"145","author":"Jensen","year":"2021","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.bonr.2025.101837_bb0220","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1158\/1078-0432.CCR-13-1941","article-title":"Anti-VEGF antibodies mitigate the development of radiation necrosis in mouse brain","volume":"20","author":"Jiang","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bonr.2025.101837_bb0225","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.bonr.2025.101837_bb0230","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.arbres.2012.01.007","article-title":"Osteonecrosis of the jaw in a patient with advanced non-small-cell lung cancer receiving bevacizumab","volume":"48","author":"Katsenos","year":"2012","journal-title":"Arch. Bronconeumol."},{"issue":"4","key":"10.1016\/j.bonr.2025.101837_bb0235","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1359\/jbmr.2001.16.4.765","article-title":"Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats","volume":"16","author":"Ke","year":"2001","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bonr.2025.101837_bb0240","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bonr.2025.101837_bb0245","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bonr.2025.101837_bb0250","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","article-title":"Osteonecrosis of the jaw related to sunitinib","volume":"15","author":"Koch","year":"2011","journal-title":"Oral Maxillofac. Surg."},{"issue":"4","key":"10.1016\/j.bonr.2025.101837_bb0255","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/bju.13924","article-title":"Anti-vascular endothelial growth factor treatment decreases bladder pain in cyclophosphamide cystitis: a Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network animal model study","volume":"120","author":"Lai","year":"2017","journal-title":"BJU Int."},{"issue":"2","key":"10.1016\/j.bonr.2025.101837_bb0260","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/tcrm.2007.3.2.341","article-title":"Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)","volume":"3","author":"Le Tourneau","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.bonr.2025.101837_bb0265","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bone.2013.10.002","article-title":"Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients","volume":"58","author":"Lescaille","year":"2014","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bonr.2025.101837_bb0270","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/8756-3282(96)00170-6","article-title":"Skeletal response to corticosteroid deficiency and excess in growing male rats","volume":"19","author":"Li","year":"1996","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bonr.2025.101837_bb0275","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1074\/jbc.M508199200","article-title":"Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF","volume":"281","author":"Liang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bonr.2025.101837_bb0280","article-title":"Zoledronic acid for prevention of bone loss in patients receiving bariatric surgery","volume":"14","author":"Liu","year":"2021","journal-title":"Bone Rep"},{"issue":"10","key":"10.1016\/j.bonr.2025.101837_bb0285","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1073\/pnas.90.10.4485","article-title":"Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts","volume":"90","author":"Lowe","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.bonr.2025.101837_bb0290","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","article-title":"Clinical pharmacokinetics of bevacizumab in patients with solid tumors","volume":"62","author":"Lu","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.bonr.2025.101837_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089770","article-title":"Murine experimental autoimmune encephalomyelitis is diminished by treatment with the angiogenesis inhibitors B20-4.1.1 and angiostatin (K1-3)","volume":"9","author":"MacMillan","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bonr.2025.101837_bb0300","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ijc.26034","article-title":"Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function","volume":"130","author":"Maita","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.bonr.2025.101837_bb0305","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"1","key":"10.1016\/j.bonr.2025.101837_bb0310","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bonr.2025.101837_bb0315","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bone.2017.12.025","article-title":"Zoledronic acid increases the prevalence of medication-related osteonecrosis of the jaw in a dose dependent manner in rice rats (Oryzomys palustris) with localized periodontitis","volume":"108","author":"Messer","year":"2018","journal-title":"Bone"},{"key":"10.1016\/j.bonr.2025.101837_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2019.115141","article-title":"Anti-vascular endothelial growth factor antibody monotherapy causes destructive advanced periodontitis in rice rats (Oryzomys palustris)","volume":"130","author":"Messer","year":"2020","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bonr.2025.101837_bb0325","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF02546241","article-title":"Ethane-1-hydroxy-1, 1-diphosphonate (EHDP). Effects on growth and modeling of the rat tibia","volume":"18","author":"Miller","year":"1975","journal-title":"Calcif. Tissue Res."},{"issue":"17","key":"10.1016\/j.bonr.2025.101837_bb0330","doi-asserted-by":"crossref","first-page":"17660","DOI":"10.1074\/jbc.M311032200","article-title":"Src kinase activity is essential for osteoclast function","volume":"279","author":"Miyazaki","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bonr.2025.101837_bb0335","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:CLIN.0000006873.65590.68","article-title":"SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model","volume":"20","author":"Murray","year":"2003","journal-title":"Clin. Exp. Metastasis"},{"issue":"5","key":"10.1016\/j.bonr.2025.101837_bb0340","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00774-021-01221-6","article-title":"Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis","volume":"39","author":"Nakamura","year":"2021","journal-title":"J. Bone Miner. Metab."},{"issue":"4","key":"10.1016\/j.bonr.2025.101837_bb0345","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clbc.2011.02.001","article-title":"Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with\/without bevacizumab","volume":"11","author":"Ngamphaiboon","year":"2011","journal-title":"Clin. Breast Cancer"},{"issue":"2","key":"10.1016\/j.bonr.2025.101837_bb0350","first-page":"383","article-title":"Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review","volume":"27","author":"Nicolatou-Galitis","year":"2019","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.bonr.2025.101837_bb0355","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1084\/jem.190.2.293","article-title":"Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption","volume":"190","author":"Niida","year":"1999","journal-title":"J. Exp. Med."},{"issue":"39","key":"10.1016\/j.bonr.2025.101837_bb0360","doi-asserted-by":"crossref","first-page":"14016","DOI":"10.1073\/pnas.0503544102","article-title":"VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice","volume":"102","author":"Niida","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.bonr.2025.101837_bb0365","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","article-title":"SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo","volume":"101","author":"O\u2019Farrell","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bonr.2025.101837_bb0370","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee","volume":"2","author":"Parfitt","year":"1987","journal-title":"J. Bone Miner. Res"},{"issue":"7","key":"10.1016\/j.bonr.2025.101837_bb0375","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s12276-019-0285-4","article-title":"RACK1 interaction with c-Src is essential for osteoclast function","volume":"51","author":"Park","year":"2019","journal-title":"Exp. Mol. Med."},{"issue":"7","key":"10.1016\/j.bonr.2025.101837_bb0380","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/0192623308326151","article-title":"Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors","volume":"36","author":"Patyna","year":"2008","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.bonr.2025.101837_bb0385","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8071579","article-title":"Osteonecrosis of the jaw associated with antiangiogenics in antiresorptive-naive patient: a comprehensive review of the literature","volume":"2018","author":"Pimolbutr","year":"2018","journal-title":"Biomed. Res. Int."},{"issue":"2","key":"10.1016\/j.bonr.2025.101837_bb0390","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s12032-011-9894-z","article-title":"A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab","volume":"29","author":"Poterucha","year":"2012","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.bonr.2025.101837_bb0395","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-019-0718-5","article-title":"Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy","volume":"12","author":"Qin","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.bonr.2025.101837_bb0400","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.bone.2011.07.017","article-title":"Issues in modern bone histomorphometry","volume":"49","author":"Recker","year":"2011","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bonr.2025.101837_bb0405","article-title":"Prevalence of medication-related osteonecrosis of the jaw in patients with breast cancer, prostate cancer, and multiple myeloma","volume":"4","author":"Rugani","year":"2016","journal-title":"Dent J (Basel)"},{"issue":"10","key":"10.1016\/j.bonr.2025.101837_bb0410","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"5","key":"10.1016\/j.bonr.2025.101837_bb0415","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American association of oral and maxillofacial surgeons\u2019 position paper on medication-related osteonecrosis of the Jaws-2022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"issue":"1","key":"10.1016\/j.bonr.2025.101837_bb0420","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/019262339902700115","article-title":"Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody","volume":"27","author":"Ryan","year":"1999","journal-title":"Toxicol. Pathol."},{"issue":"7","key":"10.1016\/j.bonr.2025.101837_bb0425","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1593\/neo.13470","article-title":"Multimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular response","volume":"15","author":"Sampath","year":"2013","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.bonr.2025.101837_bb0430","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF02547219","article-title":"Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats","volume":"11","author":"Schenk","year":"1973","journal-title":"Calcif. Tissue Res."},{"issue":"6","key":"10.1016\/j.bonr.2025.101837_bb0435","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/BF02555748","article-title":"Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat","volume":"38","author":"Schenk","year":"1986","journal-title":"Calcif. Tissue Int."},{"issue":"4","key":"10.1016\/j.bonr.2025.101837_bb0440","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/039463200902200429","article-title":"Bevacizumab-related osteneocrosis of the jaw","volume":"22","author":"Serra","year":"2009","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"4","key":"10.1016\/j.bonr.2025.101837_bb0445","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/path.4053","article-title":"Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models","volume":"227","author":"Singh","year":"2012","journal-title":"J. Pathol."},{"issue":"3","key":"10.1016\/j.bonr.2025.101837_bb0450","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1124\/dmd.111.042853","article-title":"Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans","volume":"40","author":"Speed","year":"2012","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.bonr.2025.101837_bb0455","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-004-0039-7","article-title":"Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis","volume":"75","author":"Ste-Marie","year":"2004","journal-title":"Calcif. Tissue Int."},{"issue":"35","key":"10.1016\/j.bonr.2025.101837_bb0460","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bonr.2025.101837_bb0465","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s40618-020-01269-7","article-title":"Biochemical bone turnover markers in hormonal disorders in adults: a narrative review","volume":"43","author":"Szulc","year":"2020","journal-title":"J. Endocrinol. Investig."},{"issue":"6","key":"10.1016\/j.bonr.2025.101837_bb0470","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/hep.21921","article-title":"Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats","volume":"46","author":"Tugues","year":"2007","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.bonr.2025.101837_bb0475","first-page":"2035","article-title":"RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?","volume":"19","author":"Van den Wyngaert","year":"2011","journal-title":"Support Care Cancer"},{"issue":"35","key":"10.1016\/j.bonr.2025.101837_bb0480","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario focused guideline update","volume":"35","author":"Van Poznak","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bonr.2025.101837_bb0485","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamaoncol.2020.6353","article-title":"Association of osteonecrosis of the jaw with zoledronic acid treatment for bone metastases in patients with cancer","volume":"7","author":"Van Poznak","year":"2021","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.bonr.2025.101837_bb0490","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy","volume":"360","author":"Weinstein","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bonr.2025.101837_bb0495","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bonr.2025.101837_bb0500","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/0008-5472.CAN-08-4323","article-title":"Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells","volume":"69","author":"Xin","year":"2009","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bonr.2025.101837_bb0505","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1249\/MSS.0000000000003101","article-title":"Passive cycle training promotes bone recovery after spinal cord injury without altering resting-state bone perfusion","volume":"55","author":"Yarrow","year":"2023","journal-title":"Med. Sci. Sports Exerc."},{"issue":"45","key":"10.1016\/j.bonr.2025.101837_bb0510","doi-asserted-by":"crossref","first-page":"16876","DOI":"10.1073\/pnas.0604234103","article-title":"Depression induces bone loss through stimulation of the sympathetic nervous system","volume":"103","author":"Yirmiya","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.bonr.2025.101837_bb0515","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.3892\/mmr.2014.2440","article-title":"Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549\/DDP cisplatin-resistant lung cancer cell line","volume":"10","author":"Zhang","year":"2014","journal-title":"Mol. Med. Rep."},{"issue":"6","key":"10.1016\/j.bonr.2025.101837_bb0520","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1634\/theoncologist.2014-0465","article-title":"Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor","volume":"20","author":"Zhao","year":"2015","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bonr.2025.101837_bb0525","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s12903-023-03034-7","article-title":"Anti-angiogenic drug aggravates the degree of anti-resorptive drug-based medication-related osteonecrosis of the jaw by impairing the proliferation and migration function of gingival fibroblasts","volume":"23","author":"Zhao","year":"2023","journal-title":"BMC Oral Health"}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187225000142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187225000142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T20:07:36Z","timestamp":1757534856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352187225000142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":105,"alternative-id":["S2352187225000142"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2025.101837","relation":{},"ISSN":["2352-1872"],"issn-type":[{"type":"print","value":"2352-1872"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mild antiresorptive activity of an anti-vascular endothelial growth factor A antibody and sunitinib in a rat model of bone resorption","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2025.101837","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101837"}}